The aim — of the study the efficacy and safety of ginestril at a dose of 50 mg/day in the treatment of uterine fibroids in women of reproductive age. Material and methods. A comprehensive clinical and laboratory examination and treatment of 43 patients with uterine myoma was performed. The criterion of selection in the study is conservative treatment of uterine myoma in patients of the reproductive period. All patients were divided into 2 groups: the first group consisted of patients who received gynestril at a dose of 50 mg daily orally for 6 months, treatment started on the second day of the menstrual cycle. The effectiveness of the therapy was evaluated after 6 months of treatment, 6 months after the end of the drug. The 2-nd group (comparison group) consisted of 17 patients who refused conservative and operative treatment. Results. When studying the dynamics of changes in the size of the uterus 6 months after the treatment, there was a decrease in the volume of the uterus in patients of the 1-st group by 34%, in patients of the second group of uterine size decrease was not noted. Six months after the cessation of treatment, the volume of the uterus increased insignificantly in the patients of group 1, but in comparison with the initial data, it remained less by 23%. Patients of the 2 group had no decrease in uterine size, and even 4 (23.5%) patients had a slight increase (4%) of myoma nodes. In 10 (38.4%) patients of the 1st group, a spontaneous pregnancy occurred within the first year after the end of treatment. In the second group, the pregnancy occurred in only 3 (17.6%) patients. Conclusion. Thus, the frequency of pregnancy after preparatory treatment of uterine myoma with ginestril was 2.2 times higher than in the absence of treatment. Clinical efficacy and good tolerability of the ginestril make it possible to successfully use it in the treatment of uterine fibroids in women of reproductive age in order to increase the likelihood of implementing reproductive plans.